



# Spingosine 1-Phosphate Receptor Modulators and Drug Discovery

Soo-Jin Park and Dong-Soon Im\*

Molecular Inflammation Research Center for Aging Intervention (MRCA) and College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea

## Abstract

Initial discovery on sphingosine 1-phosphate (S1P) as an intracellular second messenger was faced unexpectedly with roles of S1P as a first messenger, which subsequently resulted in cloning of its G protein-coupled receptors, S1P<sub>1-5</sub>. The molecular identification of S1P receptors opened up a new avenue for pathophysiological research on this lipid mediator. Cellular and molecular *in vitro* studies and *in vivo* studies on gene deficient mice have elucidated cellular signaling pathways and the pathophysiological meanings of S1P receptors. Another unexpected finding that fingolimod (FTY720) modulates S1P receptors accelerated drug discovery in this field. Fingolimod was approved as a first-in-class, orally active drug for relapsing multiple sclerosis in 2010, and its applications in other disease conditions are currently under clinical trials. In addition, more selective S1P receptor modulators with better pharmacokinetic profiles and fewer side effects are under development. Some of them are being clinically tested in the contexts of multiple sclerosis and other autoimmune and inflammatory disorders, such as, psoriasis, Crohn's disease, ulcerative colitis, polymyositis, dermatomyositis, liver failure, renal failure, acute stroke, and transplant rejection. In this review, the authors discuss the state of the art regarding the status of drug discovery efforts targeting S1P receptors and place emphasis on potential clinical applications.

**Key Words:** Sphingosine 1-phosphate, G protein-coupled receptor, Fingolimod, FTY720, Drug discovery, S1P agonist

## GPCR IN DRUG DISCOVERY

G protein-coupled receptors (GPCRs) constitute the largest superfamily of receptors for signaling molecules, ligands, and currently comprise some 865 receptors (Im, 2002, 2013; Fredriksson *et al.*, 2003; Kihara *et al.*, 2015). GPCRs are also known as 7TM receptors, because they have seven transmembrane domains. These receptors may signal through G proteins but they also initiate signals via other entities (Davenport *et al.*, 2013). Many ligands, including hormones, autacoids, neurotransmitters, and very small molecules to large proteins can bind and activate GPCRs, and their activations lead to a multitude of physiological processes (Howard *et al.*, 2001; Overington *et al.*, 2006; Im, 2013).

GPCRs represent a major drug target in all clinical areas. Currently, about 40% of drugs on the market target GPCRs and regulate their activities positively or negatively, because a variety of GPCRs offer selectivity and specificity for many human diseases (Im, 2013). Examples of their applications

include Claritin a H<sub>1</sub> histamine receptor antagonist, Cozaar an AT<sub>1</sub> angiotensin receptor antagonist, Neurontin a GABA<sub>B</sub>  $\gamma$ -aminobutyric acid receptor agonist, Plavix a P2Y<sub>12</sub> ADP receptor antagonist, Singulair a CysLT<sub>1</sub> leukotriene D<sub>4</sub> receptor antagonist, Zantac a H<sub>2</sub> histamine receptor antagonist, and Zyprexa a mixed D<sub>2</sub>/D<sub>1</sub>/5-HT<sub>2</sub> dopamine/serotonin receptors antagonist. About 55 GPCRs have been cloned and identified as receptors for intercellular lipid mediators, and recent studies have unearthed their functional roles under both physiological and pathological conditions (Im, 2004, 2009, 2013). Furthermore, the number of drug discovery studies being conducted on GPCRs have increased in many fields including cancer, cardiac dysfunction, central nervous system disorders, inflammatory diseases, metabolic disorders, and obesity, (Im, 2004, 2009; Mutoh *et al.*, 2012; Pyne *et al.*, 2012; Choi and Chun, 2013; Makide *et al.*, 2014; Proia and Hla, 2015). Here, we summarize current knowledge on one specific aspect of drug discovery involving interactions between GPCRs and the intercellular lipid mediator, sphingosine 1 phosphate (S1P).

**Open Access** <https://doi.org/10.4062/biomolther.2016.160>

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received Jul 22, 2016 Revised Oct 6, 2016 Accepted Oct 27, 2016  
Published Online Jan 1, 2017

\*Corresponding Author

E-mail: imds@pusan.ac.kr

Tel: +82-51-510-2817, Fax: +82-51-513-6754

## SPHINGOSINE 1-PHOSPHATE AND ITS GPCRS

S1P is a bioactive lysophospholipid metabolite that can act as an intercellular lipid mediator (Moolenaar and Hla, 2012). Initially, S1P was reported to be a second messenger that mediates increases in intracellular calcium levels as a result of PDGF and IgE signaling (Olivera and Spiegel, 1993; Choi *et al.*, 1996). However, S1P was also unexpectedly found to function as an intercellular first messenger like autacoids. The presence of S1P GPCRs in the plasma membrane was suggested by the pertussis toxin sensitivity in S1P-induced actions (Bunemann *et al.*, 1995; Goodemote *et al.*, 1995; Im *et al.*, 1997; Okajima *et al.*, 1997; van Koppen *et al.*, 1996). The discovery of S1P<sub>1</sub> (formerly known as Edg-1) in 1998 along with four other S1P<sub>2-5</sub> receptors represents a milestone in sphingolipid biology (An *et al.*, 1997; Lee *et al.*, 1998; Lynch and Im, 1999; Okamoto *et al.*, 1999; Im *et al.*, 2000; Van Brocklyn *et al.*, 2000; Yamazaki *et al.*, 2000), and leads to the identification of a variety of biological functions mediated by interactions between S1P and S1P receptors (Sanchez and Hla, 2004). In particular, S1P regulates the response and function of various cellular and organ systems, such as, cell differentiation, cell migration, cell proliferation, immune response, trafficking of T and B cells, and vascular stability (Gardell *et al.*, 2006; Huwiler and Pfeilschifter, 2008). S1P receptors exhibit overlapping or distinct expression patterns in various cells and tissues, and as a result, the various cellular functions of S1P have been assigned to S1P receptor subtypes. Furthermore, because S1P plays critical roles in autoimmune diseases, cancer, and diseases related to the cardiovascular, immune, nervous, and reproductive systems, S1P receptors become important treatment targets (Kihara *et al.*, 2015). In addition, the discovery of S1P receptors made the screening and development of S1P agonists and antagonists accessible. Furthermore, discoveries of S1P receptor subtype-selective agonists or antagonists could provide novel therapeutic candidates (Im, 2010).

The discovery that fingolimod (also known as FTY720) is an agonist of four S1P receptor subtypes by researchers in immune therapeutics field accelerated the drug discovery in this area. Fingolimod has been approved as a first-in-class drug targeting S1P<sub>1</sub> and several selective S1P receptor modulators are being subjected to clinical trials. In this review, we focus on drug discovery involving S1P receptors, especially S1P<sub>1</sub>.

## DEVELOPMENT OF S1P<sub>1</sub> RECEPTOR MODULATORS

### Fingolimod (FTY720, Gilenya®, Novartis)


Fingolimod is a well-known success of drug discovery in the S1P research field. In 1995, fingolimod was produced from the immunosuppressive natural product myriocin, which was isolated from the fungus *Isaria sinclairii* (Billich *et al.*, 2003; Im, 2003; Paugh *et al.*, 2003). In 2002, the mechanism responsible for the immunosuppressive activity of fingolimod was determined to be due to the regulation of lymphocyte trafficking in a rodent model of multiple sclerosis (Brinkmann *et al.*, 2002). Fingolimod, through S1P<sub>1</sub>, was found to directly alter the trafficking of naïve and antigen-activated CD4<sup>+</sup> T cells and to control egress of lymphocytes from secondary lymphoid tissues and endothelial barrier function (Xie *et al.*, 2003; Brinkmann *et al.*, 2004; Chiba, 2005). In 2010, the Food and Drug Administration (FDA) approved fingolimod as the first oral

disease-modifying drug to treat relapses of multiple sclerosis (Kihara *et al.*, 2015). Multiple sclerosis is a demyelinating disease that damages axonal myelin sheaths in the brain and spinal cord. The primary action mechanism of fingolimod is to reduce lymphocyte egress from secondary lymphoid organ, thymus, and bone marrow, resulting in lymphopenia (Adachi and Chiba, 2008). Thereby, lymphopenia contributes to inhibit axon myelin sheath damage.

Fingolimod is a unique drug in two respects. First, fingolimod is a prodrug (Fig. 1). *In vivo* fingolimod is phosphorylated by sphingosine kinases (SK1 and SK2) and then phosphorylated fingolimod acts as an agonist on four S1P receptor subtypes (S1P<sub>1</sub>, S1P<sub>3</sub>, S1P<sub>4</sub> and S1P<sub>5</sub>) (Billich *et al.*, 2003). Second, effects of fingolimod on lymphocyte egress involve not agonistic but rather functional antagonistic activity against S1P<sub>1</sub> (Fig. 1) (Matloubian *et al.*, 2004). Both S1P and fingolimod-phosphate have been reported to induce lymphopenia via the agonistic activation of S1P<sub>1</sub> and subsequent internalization of S1P<sub>1</sub> in the lymphocytes (Brinkmann *et al.*, 2004; Thangada *et al.*, 2010). In fact, the absence of S1P<sub>1</sub> on the cell surface blocks re-circulation of lymphocytes from secondary lymphoid organs to blood, because lymphocytes egress by chemotactic response to S1P concentration gradient (high in blood and low in lymph node) through S1P<sub>1</sub> (Brinkmann *et al.*, 2004; Chiba, 2009). In the case of S1P<sub>1</sub> agonist like S1P, internalized S1P<sub>1</sub> recycled back to the cell surface within several hours. However, in the case of S1P<sub>1</sub> modulators like fingolimod-phosphate, internalized S1P<sub>1</sub> undergoes proteosomal degradation, resulting in long-time absence of S1P<sub>1</sub> until *de novo* synthesized (Oo *et al.*, 2007). This kind of functional antagonism of fingolimod means it has a long action time, which can sometimes be disadvantageous (Subei and Cohen, 2015). The immune modulatory action of fingolimod has also been reported in autoimmune diseases other than multiple sclerosis, such as spontaneous autoimmune polyneuropathy and experimental autoimmune neuritis (Kim *et al.*, 2009; Zhang *et al.*, 2009a).

Other applications of fingolimod have also been suggested, such as, for the treatment of ischemia/reperfusion injury, which is the cellular damage that results from ischemia and re-supply of blood to infarcted tissues. In fact, it has been estimated that systemic inflammatory response after ischemia/reperfusion may account for 30-40% of intensive care unit mortalities (Eltzschig and Collard, 2004). In one animal study, fingolimod significantly inhibited leukocyte infiltration, peripheral blood lymphocyte counts, and vascular permeability in renal ischemia/reperfusion injury (Awad *et al.*, 2006). In other studies, fingolimod attenuated arterial pressure and improved organ function when it was applied to heart or lung ischemia/reperfusion (Hofmann *et al.*, 2009; Stone *et al.*, 2015). Recently, fingolimod was reported to inhibit hypoxia/reperfusion-induced cardiomyocyte apoptosis by inhibiting caspase 3 activation, and by activating Akt and Erk signaling through S1P<sub>1/3</sub> activation (Wang *et al.*, 2014). These preclinical studies indicate that fingolimod has potential to be used for the treatment of ischemia/reperfusion injury and autoimmune disorders.

Fingolimod has been reported to attenuate neuroinflammation by regulating the activation and neuroprotective effects of microglia mainly via S1P<sub>1</sub> (Jackson *et al.*, 2011; Noda *et al.*, 2013; Kolahdooz *et al.*, 2015). In addition, fingolimod is known to inhibit allergen-induced airway inflammation and hyper-reactivity in mice (Ble *et al.*, 2009; Marsolais *et al.*, 2011; Trifilieff and Fozard, 2012). Furthermore, in low-density lipoprotein



**Fig. 1.** Action mechanism of fingolimod and other S1P receptor modulators. Fingolimod is transformed to fingolimod-phosphate *in vivo* by sphingosine kinases. Fingolimod-phosphate can activate S1P<sub>1</sub>, S1P<sub>3</sub>, S1P<sub>4</sub>, and S1P<sub>5</sub>, and the fingolimod activation of S1P<sub>1</sub> in lymphocytes leads to GRK2-mediated phosphorylation of C-terminal tail of S1P<sub>1</sub>, which recruits β-arrestin and induces S1P<sub>1</sub> internalization. This internalization exposes S1P<sub>1</sub> to proteosomal degradation, which prevents the recycling of S1P<sub>1</sub> and results in the loss of S1P<sub>1</sub> from the plasma membrane. This absence of S1P<sub>1</sub> blocks lymphocyte egression from secondary lymphoid organs and reduces T and B cell counts in the blood. Lymphopenia is presumed to be the main mechanism whereby fingolimod causes immune suppression in autoimmune diseases like relapsing multiple sclerosis.

(LDL) receptor-deficient mice, fingolimod significantly attenuated atherosclerotic lesion formation, necrotic core formation, and lymphocyte function (Nofer *et al.*, 2007). And peritoneal macrophages isolated from fingolimod-treated mice showed more of the M2 macrophage phenotype and less of the M1 macrophage phenotype (Nofer *et al.*, 2007). However, Poti *et al.* (2012) reported in LDL receptor-deficient mice fed a Western diet, fingolimod reduced macrophage function, weight gain, and white adipose tissue amount, but failed to affect atherosclerosis.

A phase 3 clinical trial on fingolimod for primary progressive multiple sclerosis (INFORMS; NCT00731692) showed that it has anti-inflammatory effects but fails to reduce disease progression (Lublin *et al.*, 2016). In addition, a phase 2 clinical trial for its effects on pulmonary function in moderate asthma patients was completed in 2009 (NCT00785083).

In a pilot study conducted in patients with acute ischemic stroke, fingolimod/alteplase combination therapy was well tolerated, attenuated reperfusion injury, and improved clinical outcomes (Fu *et al.*, 2014; Li *et al.*, 2015; Zhu *et al.*, 2015). Fingolimod is now under a phase 2 clinical trial for acute stroke (NCT02002390). In addition, fingolimod is currently under phase 2 clinically testing in Rett's syndrome (NCT02061137), phase 2 schizophrenia (NCT01779700), phase 4 neurodegeneration (NCT02575365), and multiple sclerosis (Table 1).

Several side effects of fingolimod have been reported in

three phase 3 trials (FREEDOMS, FREEDOM II, and TRANSFORMS) (Kappos *et al.*, 2010; Calabresi *et al.*, 2014; Cohen *et al.*, 2016b). The common adverse effects were bradycardia at the first dose or atrioventricular block, macular edema, hypertension, headache, cough, dyspnea, back pain, influenza, and diarrhea (Subei and Cohen, 2015). First dose bradycardia is believed to be mediated via transient S1P<sub>1</sub> activation in atrial myocytes, which would disappear by down-regulation of S1P<sub>1</sub> (Camm *et al.*, 2014). Unlike in man, S1P<sub>3</sub> in atrial myocytes causes bradycardia in mice (Forrest *et al.*, 2004; Sanna *et al.*, 2004). Other adverse effects of fingolimod may be due to off-target effects via other S1P receptors, as it is a non-selective S1P agonist (S1P<sub>1, 3-5</sub>) (Brinkmann *et al.*, 2002). Therefore, currently several S1P<sub>1</sub> selective agonists/modulators are being developed as drug candidates in the wake of fingolimod (Fig. 1).

### SEW2871

SEW2871 is a highly selective S1P<sub>1</sub> agonist, which does not act on S1P<sub>2-5</sub>. As was expected, SEW2871 has been reported to reduce lymphocyte numbers in blood (Wei *et al.*, 2005; Kim *et al.*, 2009). As like fingolimod, SEW2871 also ameliorated ischemic acute renal failure after ischemia/reperfusion injury in mice (Lien *et al.*, 2006). SEW2871 was also found to protect heart and liver tissues after myocardial or hepatic ischemia/reperfusion injury and these protective effects were ascribed

**Table 1.** Summary of S1P receptor modulators currently undergoing or completed in clinical trials (based on data at <http://www.clinicaltrials.gov/> in July 2016)

Chemical	Target	Condition	Stage	Status	NLM ID
Fingolimod (FTY-720)	S1P <sub>1/3/4/5</sub>	Relapsing remitting multiple sclerosis (RRMS)		Approved (2010)	
		Neurodegeneration	Phase IV	Active	NCT02575365
		Schizophrenia	Phase II	Active	NCT01779700
		Rett Syndrome	Phase II	Active	NCT02061137
		Acute Stroke	Phase II	Active	NCT02002390
		Amyotrophic lateral sclerosis	Phase II	Completed (2015)	NCT01786174
		Primary progressive multiple sclerosis	Phase III	Completed (2014)	NCT00731692
		Renal insufficiency	Phase I	Completed (2011)	NCT00731523
		Moderate asthma	Phase II	Completed (2009)	NCT00785083
		Renal/Kidney transplantation	Phase III	Completed (2006)	NCT00099801
		KRP-203	S1P <sub>1</sub>	Subacute cutaneous lupus erythematosus	Phase II
Hematological malignancies	Phase I			Active	NCT01830010
Siponimod (BAF312)	S1P <sub>1/5</sub>	Secondary progressive multiple sclerosis	Phase III	Active	NCT01665144
		RRMS	Phase II	Completed (2012)	NCT00879658
		- (Extension) -		- Active -	NCT01185821
		Polymyositis	Phase II	Active	NCT01801917
		Active dermatomyositis	Phase II	Completed (2016)	NCT02029274
		Hepatic impairment	Phase I	Completed (2014)	NCT01565902
		Renal impairment	Phase I	Completed (2014)	NCT01904214
CS-0777	S1P <sub>1</sub>	Multiple sclerosis	Phase I	Completed (2010)	NCT00616733
Ponesimod (ACT-128800)	S1P <sub>1</sub>	RRMS	Phase II	Active	NCT01093326
		Ponesimod vs teriflunomide in RRMS	Phase III	Active	NCT02425644
		Chronic GVHD	Phase II	Active	NCT02461134
Ozanimod (RPC1063)	S1P <sub>1/5</sub>	Psoriasis	Phase II	Completed (2012)	NCT01208090
		Multiple sclerosis	Phase III	Active	NCT02047734
		Ulcerative colitis	Phase III	Active	NCT02435992
Ceralifimod (ONO-4641)	S1P <sub>1/5</sub>	Crohn's disease	Phase II	Active	NCT02531113
		RRMS	Phase II	Completed (2011)	NCT01081782
GSK2018682	S1P <sub>1/5</sub>	- (Extension) -	Phase II	Terminated(2015)	NCT01226745
		RRMS	Phase I	Completed (2011)	NCT01466322
MT-1303	S1P <sub>1</sub>	Crohn's disease	Phase II	Active	NCT02378688
		Systemic lupus erythematosus	Phase I	Active	NCT02307643
		RRMS	Phase II	Completed (2014)	NCT01742052
		Plaque psoriasis	Phase II	Completed (2014)	NCT01987843
		Inflammatory bowel disease	Phase I	Completed (2014)	NCT01666327

RRMS, relapsing remitting multiple sclerosis.

to S1P<sub>1</sub> activation (Hofmann *et al.*, 2009; Park *et al.*, 2010).

Several preclinical studies have shown SEW2871 has therapeutic implications in contexts of diabetes, Alzheimer's disease, liver fibrosis, and inflammatory responses. In a non-obese mouse model of type 1 diabetes, SEW2871 inhibited monocyte adhesion to diabetic aortas and prevented monocyte/endothelial interactions, which suggests SEW2871-induced S1P<sub>1</sub> signaling has potential for treatment of the vascular complications of type 1 diabetes (Whetzel *et al.*, 2006). In a rat model of Alzheimer's disease, chronic SEW2871 admin-

istration inhibited  $\beta$  amyloid (A $\beta$ <sub>1-42</sub>)-induced spatial memory impairment and hippocampal neuronal loss, indicating the S1P<sub>1</sub> signaling pathway offers a novel therapeutic target for the prevention of neurodegenerative disorders (Asle-Rousta *et al.*, 2013).

SEW2871 was also found to modulate liver fibrosis by directly regulating the migration of human hepatic myofibroblasts into the damaged areas (Li *et al.*, 2011). In LX-2 cells (a human hepatic stellate cell line), SEW2871 exerted a powerful migratory effect by increasing smooth muscle  $\alpha$ -actin, procol-

lagen  $\alpha$ I and  $\alpha$ III, and total hydroxyproline contents (Liu *et al.*, 2011). It has also been reported SEW2817 has the following anti-inflammatory effects; it inhibits dendritic cell chemotaxis and migration to lymph nodes, causes switching to the M2 macrophage phenotype, and decreases proinflammatory cytokine levels under inflammatory conditions (Gollmann *et al.*, 2008; Hughes *et al.*, 2008). The intravenous administration of SEW2871 was found to attenuate LPS-induced acute inflammatory lung injury (Sammani *et al.*, 2010). Therefore, multiple applications have been suggested for S1P<sub>1</sub> agonists.

### KRP-203

KRP-203 is an immunosuppressive S1P<sub>1</sub> agonist with a molecular structure similar to that of fingolimod (Shimizu *et al.*, 2005). Like fingolimod and SEW2871, KRP-203 can regulate lymphocyte homing and has an immunosuppressive activity (Shimizu *et al.*, 2005). The action mechanism of KRP-203 is identical to that of fingolimod, that is, it involves the *in vivo* phosphorylation and functional antagonism of S1P<sub>1</sub>. Furthermore, KRP-203-phosphate has an agonistic effect on S1P<sub>5</sub> like S1P<sub>1</sub>, but not S1P<sub>2-4</sub> (Lukas *et al.*, 2014). KRP-203 has been developed for use in organ transplantation. In 2005, KRP-203 was reported to prolong graft survival significantly and to reduce chronic rejection and graft vasculopathy in rat skin and heart allografts (Shimizu *et al.*, 2005; Takahashi *et al.*, 2005), and in 2006, it was suggested to be a potential immune modulator after rat renal transplantation (Fujishiro *et al.*, 2006).

KRP-203 has also been applied in several experimental models for autoimmune disorders and inflammatory bowel diseases. In a rat experimental autoimmune myocarditis model, KRP-203 significantly inhibited the infiltrations of macrophages and CD4<sup>+</sup> T cells into myocardium, and reduced areas of inflammation (Ogawa *et al.*, 2007). In a murine model of concanavalin A-induced autoimmune hepatitis, KRP-203 increased lymphocyte sequestration in secondary lymph nodes and decreased numbers of CD4<sup>+</sup> lymphocytes in liver (Kaneko *et al.*, 2006).

The effects of KRP-203 have also been examined in inflammatory disorders, such as, Crohn's disease and atherosclerosis. In an interleukin (IL)-10 gene-deficient (IL-10<sup>-/-</sup>) mouse model of chronic colitis, KRP-203 inhibited body weight loss and proinflammatory cytokine production, suppressed lymphocyte infiltration at inflammatory sites, and prevented chronic colitis (Song *et al.*, 2008). In LDL receptor-deficient mice on cholesterol-rich diet, KRP-203 dramatically suppressed atherosclerotic lesion formation and induced lymphopenia, and *in vitro*, inhibited tumor necrosis factor- $\alpha$ , IL-6, and interferon- $\gamma$ -induced protein-10 (Poti *et al.*, 2013).

Currently, KRP-203 is undergoing a phase 2 clinical trial for subacute lupus erythematosus (NCT01294774), and a phase 1 clinical trial to evaluate its safety, tolerability, pharmacokinetics, and efficacy in patients undergoing stem cell transplantation for hematological malignancies (NCT01830010) (Table 1).

### AUY954

AUY954 is an aminocarboxylate analogue of fingolimod and a potent and selective S1P<sub>1</sub> agonist (Pan *et al.*, 2006). AUY954 has been demonstrated to have beneficial effects after rat heart transplantation, in experimental autoimmune neuritis, and on lung inflammation. In a stringent rat trans-

plantation model, AUY954 decreased circulating lymphocytes and prolonged cardiac allograft survival (Pan *et al.*, 2006). In addition, in an animal model of experimental autoimmune neuritis (a T cell-mediated autoimmune inflammatory demyelinating disease of nervous system), AUY954 sequestered lymphocytes into secondary lymphoid tissues and significantly inhibited inflammatory demyelination, immune cell infiltration, and expressions of IL-17 and metalloproteinase-9 in rat sciatic nerves (Zhang *et al.*, 2009b).

The actions of AUY954 in respiratory disorders are complicated. In an allergen-induced airway inflammation model, intranasal administration of AUY954 inhibited lymphocyte accumulation in bronchoalveolar lavage fluid, but no effect on eosinophils (Ble *et al.*, 2009). On the other hand, AUY954 inhibited airway chemokine release and accumulations of activated T cells and eosinophils in ovalbumin-induced eosinophilic airway inflammation (Marsolais *et al.*, 2011). However, prolonged exposure of AUY954 dramatically worsened lung injury, vascular leak, and mortality in a mouse model of bleomycin-induced lung injury, and repeated AUY954 administration increased pulmonary fibrosis by inducing vascular leak (Shea *et al.*, 2010). This cautions the effects of S1P<sub>1</sub> modulators on respiratory disorders require careful interpretation.

### Siponimod (BAF312)

Siponimod (also known as BAF312) is a novel alkoxyimino derivative and an agonist of S1P<sub>1</sub> and S1P<sub>5</sub> (Gergely *et al.*, 2012). Siponimod is being investigated in the context of multiple sclerosis (Subei and Cohen, 2015). Like fingolimod, siponimod induces lymphopenia by preventing lymphocyte egress from lymph nodes (Fryer *et al.*, 2012). In addition, siponimod was found to completely suppress experimental autoimmune encephalomyelitis in a rat model (Gergely *et al.*, 2012), and in another study, to inhibit LPC-induced demyelination in organotypic slice cultures and attenuate LPS or TNF $\alpha$ /IL-17-induced IL-6 production in astrocytes and microglia (O'Sullivan *et al.*, 2016). These findings suggest that siponimod and fingolimod may act directly through brain cells as well as through lymphopenia (Choi *et al.*, 2011; O'Sullivan *et al.*, 2016).

In healthy individuals, siponimod reduced T and B cell numbers in blood within 4-6 h, and numbers recovered to basal levels within a week after stopping treatment (Gergely *et al.*, 2012). Siponimod may be an effective treatment for immune-mediated diseases. Initial and extended phase 2 clinical trials in patients with relapsing-remitting multiple sclerosis (BOLD) have been successfully completed (NCT 00879658, NCT01185821) (Selmaj *et al.*, 2013; Kappos *et al.*, 2016).

Currently, siponimod is undergoing a phase 3 efficacy and safety clinical trial in patients with secondary progressive multiple sclerosis (NCT01665144) along with mechanistic studies of phase 3 trial (NCT02330965). Also a phase 2 efficacy and tolerability clinical trial for polymyositis is undergoing (NCT01801917). A phase 2 clinical trial for dermatomyositis (NCT02029274), and two phase 1 pharmacokinetic trials for renal and hepatic impairments (NCT01904214 and NCT01565902) have been completed (Table 1).

### CS-0777

CS-0777 is a selective S1P<sub>1</sub> modulator that is currently being developed for the treatment of autoimmune diseases such as multiple sclerosis (Moberly *et al.*, 2012a). CS-0777 is phosphorylated *in vivo*, and the phosphorylated CS-0777 acts as

a selective S1P<sub>1</sub> agonist like fingolimod (Nishi *et al.*, 2011). CS-0777 has also been investigated in multiple sclerosis, like almost all other S1P<sub>1</sub> agonists, it induces lymphopenia and suppresses experimental autoimmune encephalomyelitis (Nishi *et al.*, 2011). In an open-label, pilot phase 1, clinical trial on healthy individuals and multiple sclerosis patients, oral CS-0777 decreased numbers of lymphocytes and CD4<sup>+</sup> T cells in blood, and levels returned to normal condition within 4 weeks of discontinuation (NCT00616733) (Moberly *et al.*, 2012a, 2012b) (Table 1).

### Ponesimod (ACT-128800)

Ponesimod is an orally active, selective S1P<sub>1</sub> agonist that induces sequestration of lymphocytes into lymphoid organs (Bolli *et al.*, 2010). In contrast to the long half-life and slow elimination of fingolimod, ponesimod is eliminated within 1 week after discontinuation and its pharmacological effects are rapidly reversible (D'Ambrosio *et al.*, 2016).

The clinical pharmacology of ponesimod has been described in several studies. In lymphocyte-mediated inflammatory diseases, ponesimod reduced several types of inflammation response, including edema formation, inflammatory cell infiltration, and proinflammatory cytokine levels (Piali *et al.*, 2011). In addition, in a non-obese diabetic mouse model of autoimmune diabetes, ponesimod protected against disease development by reducing numbers of B and T cells in blood and spleen (You *et al.*, 2013). Ponesimod is viewed as a potential new therapeutic strategy for autoimmune disorders. Once-daily treatment (10, 20 or 40 mg) significantly reduced the number of new T1 Gd<sup>+</sup> lesions and had beneficial effects on clinical endpoints in relapsing-remitting multiple sclerosis (NCT01006265) (Olsson *et al.*, 2014). Currently, a long-term safety phase 2 clinical trial in relapsing-remitting multiple sclerosis (NCT01093326) and a phase 3 oral ponesimod vs teriflunomide trial in relapsing multiple sclerosis (NCT02425644) are being conducted.

Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin, which are typically itchy, red, and scaly. Because psoriasis is a T cell-mediated inflammatory skin disease, studies on ponesimod have been conducted in this context. In particular, a randomized, double-blind, placebo-controlled phase 2 clinical trial showed the efficacy, safety, and tolerability of oral ponesimod in chronic plaque psoriasis (NCT01208090) (Vaclavkova *et al.*, 2014).

Ponesimod is also under phase 2 clinical trial for chronic graft-versus-host disease (GVHD) (NCT02461134), which is a complication encountered after stem cell or bone marrow transplantation. GVHD has autoimmune-like features and chronic GVHD involves both autoreactive and alloreactive T and B cells. In GVHD, newly transplanted donor cells attack the transplant recipient's body. As S1P<sub>1</sub> modulators suppress vascular damage and immune cell accumulation in skin, and thus, reduce immune response (Huu *et al.*, 2013), they offer potential means to targeting GVHD.

### Ozanimod (RPC1063)

Ozanimod is an oral selective S1P<sub>1/5</sub> dual modulator, and induces lymphopenia and regulates immune response (Scott *et al.*, 2016). In three models of autoimmune diseases that is, experimental autoimmune encephalitis, TNBS-induced colitis, and CD4<sup>+</sup> CD45RBhi T cell adaptive transfer colitis, oral ozanimod diminished inflammation parameters. This finding sup-

ports the clinical development of ozanimod for multiple sclerosis (Cohen *et al.*, 2016a; Scott *et al.*, 2016).

Inflammatory bowel disease is a disease of the small intestine and colon and is classified as Crohn's disease or ulcerative colitis. Crohn's disease affects the entire gastrointestinal tract, whereas ulcerative colitis usually affects colon and rectum. Because inflammatory bowel disease is a type of autoimmune disease, it is considered immunosuppression may allow control of its symptoms. Ozanimod induces peripheral lymphocyte sequestration and reduces circulating lymphocyte counts in the gastrointestinal tract (Rivera-Nieves, 2015). In a double-blind, placebo-controlled phase 2 trial in ulcerative colitis, ozanimod induced a significantly higher rate of clinical remission than a placebo (NCT01647516) (Sandborn *et al.*, 2016), which suggests S1P<sub>1</sub> modulation offers a means of treating inflammatory bowel disease. Currently, ozanimod is under phase 3 trials in relapsing multiple sclerosis (NCT02047734) and moderate to severe ulcerative colitis (NCT02435992), and a phase 2 trial in moderate to severe Crohn's disease (NCT02531113) (Table 1).

### Ceralifimod (ONO-4641)

Ceralifimod is a selective S1P<sub>1/5</sub> dual agonist (Ohno *et al.*, 2010). Like fingolimod, it suppresses peripheral blood lymphocyte counts in rats by inhibiting lymphocyte egress from secondary lymphoid tissues (Ohno *et al.*, 2010). Ceralifimod was also found to prevent relapsing-remitting experimental autoimmune encephalomyelitis in a non-obese diabetic mouse model (Ohno *et al.*, 2010; Komiya *et al.*, 2013). A phase 2 clinical trial of ceralifimod was completed for relapsing-remitting multiple sclerosis (NCT01081782) in 2011. However, a phase 2 safety and efficacy extension study of ceralifimod was terminated by developers (NCT01226745) (Subei and Cohen, 2015).

### GSK2018682

GSK2018682 is a potent S1P<sub>1</sub> and S1P<sub>5</sub> agonist (Xu *et al.*, 2014). In an experimental autoimmune encephalomyelitis mouse model, GSK2018682 and fingolimod exhibited similar efficacy. A phase 1 clinical trial on GSK2018682 for relapsing-remitting multiple sclerosis was completed in 2011 (NCT01466322).

### MT-1303

MT-1303 is a selective S1P<sub>1</sub> modulator (a functional antagonist) that is undergoing development. MT-1303 has been subjected to a phase 2 study in moderate to severe chronic plaque psoriasis (NCT01987843), a phase 2 study of MT-1303 in relapsing-remitting multiple sclerosis (NCT01742052), and a phase 1 for inflammatory bowel disease (NCT01666327). Currently, phase 2 clinical trials are being conducted for Crohn's disease (NCT02378688) and systemic lupus erythematosus (NCT02307643) (Table 1 and [www.clinicaltrials.gov](http://www.clinicaltrials.gov)).

## DEVELOPMENT OF S1P RECEPTOR ANTAGONIST

### JTE-013

JTE-013 is a potent, selective S1P<sub>2</sub> antagonist that has no effect on the other four S1P receptors (Osada *et al.*, 2002), and has been mainly used to study the roles and functions of S1P<sub>2</sub> in different cell types and diseases.

It has been established that S1P affects various cellular

responses in endothelial cells, such as, cytoskeletal re-structuring and cell-extracellular/intracellular matrix interactions. S1P<sub>2</sub> signaling is involved in microvascular permeability, and it has been reported JTE-013 inhibition of S1P<sub>2</sub> significantly inhibited microvascular permeability in an *in vivo* animal model and regulated endothelial tight junctions and barrier function *in vitro* (Lee *et al.*, 2009). In a recent preclinical study, JTE-013 modulated the responses of brain endothelium by inhibiting cerebrovascular permeability, the development of intracerebral hemorrhage, and neurovascular injury in an experimental model of stroke (Kim *et al.*, 2015). After injecting the myotoxic drug notexin to induce muscle degeneration, JTE-013 treatment delayed regeneration of muscle and reduced levels of myogenin (a muscle differentiation marker), and the phosphorylation of Akt (a key marker of muscle growth) (Germinario *et al.*, 2012). Therefore, S1P<sub>2</sub> signaling plays an important role in microvascular permeability and muscle regeneration.

During allergic response in lung, mast cells contain many granules rich in histamine and heparin, and thus, play central roles in various allergic diseases and anaphylaxis. S1P<sub>2</sub> expressed in mast cells was found to be involved in S1P-induced RBL-2H3 mast cell migration (Yokoo *et al.*, 2004). JTE-013 also inhibited responses to ovalbumin and allergen-induced mast cell activation in rats (Trifilieff *et al.*, 2009). Treatment with JTE-013 attenuated IgE-stimulated anaphylactic responses and pulmonary edema in mice (Oskeritzian *et al.*, 2010), and in *in vitro* and *in vivo* studies, JTE-013 reduced mast cell activation, airway infiltration, and the serum levels of histamine and several cytokines (Oskeritzian *et al.*, 2015). In addition, JTE-013 has been reported to inhibit S1P-induced fibroblast chemotaxis, Rho activation, and focal adhesion kinase phosphorylation, which all affect tissue repair after injury (Hashimoto *et al.*, 2008). JTE-013 also blocked S1P-induced inhibition of migration and Rac1-dependent signaling pathway in human bronchial smooth muscle cells (Kawata *et al.*, 2005). These findings suggest that S1P<sub>2</sub> antagonism offers a novel means of treating airway allergic diseases.

Pancreatic  $\beta$  cell dysfunction contributes to the development of insulin resistance and of type 2 diabetes, and several authors have reported relations between S1P<sub>2</sub> and type 2 diabetes. In a murine model, JTE-013 suppressed streptozotocin-induced blood glucose increases, pancreatic  $\beta$  cell apoptosis, and the incidence of diabetes (Imasawa *et al.*, 2010). Furthermore, JTE-013 protected pancreatic  $\beta$  cells in a New Zealand obese diabetic mouse model under high-fat diet conditions (Japtok *et al.*, 2015). Levels of plasminogen activator inhibitor-1, which is produced from adipocytes, are increased in obese individuals. Interestingly, JTE-013 suppressed plasminogen activator inhibitor-1 increases in mouse 3T3-L1 adipocytes (Ito *et al.*, 2013), and S1P<sub>2</sub> deficient mice fed a high-fat diet had better glucose/insulin tolerance test results and smaller epididymal adipocytes (Kitada *et al.*, 2016). These results suggest JTE-013 might be useful for treating obesity and type 2 diabetes.

Treatment with JTE-013 also reduced plasma levels of IL-1 $\beta$  and IL-18 (endotoxin-induced inflammatory cytokines) in ApoE<sup>-/-</sup> mice and S1P<sub>2</sub> gene deficiency reduced atherosclerosis (Skoura *et al.*, 2011). Furthermore, JTE-013 modulated the permeability and inflammatory responses of the vascular endothelium during endotoxemia (Zhang *et al.*, 2013), and S1P<sub>2</sub> was suggested to be a critical receptor in macrophages due to its impairment of phagocytosis and antimicrobial defense

during the pathogenesis of sepsis (Hou *et al.*, 2015). These findings indicate JTE-013 offers a novel means of treating inflammatory disorders, such as, atherosclerosis and sepsis.

## CLOSING REMARK

The discovery of S1P receptors and subsequent finding of fingolimod as a modulator of S1P<sub>1</sub> receptor successfully linked to the FDA approval of fingolimod as a first orally active drug treating relapsing multiple sclerosis. The commercial release of fingolimod stimulated pharmaceutical researchers to develop better drugs targeting S1P<sub>1</sub> in terms of efficacy and safety, and these efforts have resulted in multiple drug candidates for clinical trials (Table 1). Much effort has been made to overcome the non-selectivity of fingolimod, which acts on S1P<sub>1</sub> and S1P<sub>3-5</sub>, and as a result S1P<sub>1</sub> monoselective agonists, such as AUY954, CS-0777, KRP-203, SEW2871, ponesimod, and MT-1303, have been developed. Dual agonists on S1P<sub>1</sub> and S1P<sub>5</sub> have also been produced, such as, ceralifimod, siponimod, ozanimod, and GSK2018682. The first clinical approval issued for fingolimod was for the treatment of relapsing multiple sclerosis. Currently, fingolimod and other S1P<sub>1</sub> modulators are being developed for autoimmune disease and for inflammatory disorders, such as, plaque psoriasis, dermatomyositis, Crohn's disease, ulcerative colitis, polymyositis, liver failure, renal failure, acute stroke, GVHD, and transplant rejection. Because these exhibit greater selectivity for S1P<sub>1</sub> than fingolimod, it is hoped that they will cause fewer adverse effects and be more effective. We are confident that in near future, more S1P receptor modulators will be approved for the treatment of disorders associated with autoimmune and inflammation.

## ACKNOWLEDGMENTS

This research was supported by the Basic Science Research Program of the Korean National Research Foundation funded by the Korean Ministry of Education, Science and Technology (NRF-2016R1D1A1A009917086) and by the Korean National Research Foundation funded by the Korean government (MSIP) (Grant no. 2009-0083538).

## REFERENCES

- Adachi, K. and Chiba, K. (2008) FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. *Perspect. Medicin. Chem.* 1, 11-23.
- An, S., Bleu, T., Huang, W., Hallmark, O. G., Coughlin, S. R. and Goetzl, E. J. (1997) Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. *FEBS Lett.* 417, 279-282.
- Asle-Rousta, M., Oryan, S., Ahmadiani, A. and Rahnama, M. (2013) Activation of sphingosine 1-phosphate receptor-1 by SEW2871 improves cognitive function in Alzheimer's disease model rats. *EXCLI J.* 12, 449-461.
- Awad, A. S., Ye, H., Huang, L., Li, L., Foss, F. W., Jr., Macdonald, T. L., Lynch, K. R. and Okusa, M. D. (2006) Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. *Am. J. Physiol. Renal Physiol.* 290, F1516-F1524.
- Billich, A., Bornancin, F., Devay, P., Mechtcheriakova, D., Urtz, N. and Billich A1, Bornancin, F., Dévay, P., Mechtcheriakova, D., Urtz, N.

- and Baumruker, T. (2003) Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. *J. Biol. Chem.* **278**, 47408-47415.
- Ble, F. X., Cannet, C., Zurbrugg, S., Gerard, C., Frossard, N., Beckmann, N. and Triffilleff, A. (2009) Activation of the lung S1P<sub>1</sub> receptor reduces allergen-induced plasma leakage in mice. *Br. J. Pharmacol.* **158**, 1295-1301.
- Bolli, M. H., Abele, S., Binkert, C., Bravo, R., Buchmann, S., Bur, D., Gatfield, J., Hess, P., Kohl, C., Mangold, C., Mathys, B., Menyhart, K., Muller, C., Nayler, O., Scherz, M., Schmidt, G., Sippel, V., Steiner, B., Strasser, D., Treiber, A. and Weller, T. (2010) 2-iminothiazolidin-4-one derivatives as potent, orally active S1P<sub>1</sub> receptor agonists. *J. Med. Chem.* **53**, 4198-4211.
- Brinkmann, V., Cyster, J. G. and Hla, T. (2004) FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. *Am. J. Transplant.* **4**, 1019-1025.
- Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., Foster, C. A., Zollinger, M. and Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., Foster, C. A., Zollinger, M. and Lynch, K. R. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. *J. Biol. Chem.* **277**, 21453-21457.
- Bunemann, M., Brandts, B., zu Heringdorf, D. M., van Koppen, C. J., Jakobs, K. H. and Pott, L. (1995) Activation of muscarinic K<sup>+</sup> current in guinea-pig atrial myocytes by sphingosine-1-phosphate. *J. Physiol.* **489**, 701-707.
- Calabresi, P. A., Radue, E. W., Goodin, D., Jeffery, D., Rammohan, K. W., Reider, A. T., Vollmer, T., Agius, M. A., Kappos, L., Stites, T., Li, B., Cappiello, L., von Rosenstiel, P. and Lublin, F. D. (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol.* **13**, 545-556.
- Camm, J., Hla, T., Bakshi, R. and Brinkmann, V. (2014) Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. *Am. Heart J.* **168**, 632-644.
- Chiba, K. (2005) FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. *Pharmacol. Ther.* **108**, 308-319.
- Chiba, K. (2009) New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720). *Yakugaku zasshi* **129**, 655-665.
- Choi, J. W. and Chun, J. (2013) Lysophospholipids and their receptors in the central nervous system. *Biochim. Biophys. Acta* **1831**, 20-32.
- Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C. W., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G. and Chun, J. (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P<sub>1</sub>) modulation. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 751-756.
- Choi, O. H., Kim, J. H. and Kinet, J. P. (1996) Calcium mobilization via sphingosine kinase in signalling by the Fc epsilon RI antigen receptor. *Nature* **380**, 634-636.
- Cohen, J. A., Arnold, D. L., Comi, G., Bar-Or, A., Gujrathi, S., Hartung, J. P., Cravets, M., Olson, A., Frohna, P. A. and Selmaj, K. W. (2016a) Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. *Lancet Neurol.* **15**, 373-381.
- Cohen, J. A., Khatri, B., Barkhof, F., Comi, G., Hartung, H. P., Montalban, X., Pelletier, J., Stites, T., Ritter, S., von Rosenstiel, P., Tomic, D. and Kappos, L. (2016b) Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. *J. Neurol. Neurosurg. Psychiatr.* **87**, 468-475.
- D'Ambrosio, D., Freedman, M. S. and Prinz, J. (2016) Ponesimod, a selective S1P<sub>1</sub> receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. *Ther. Adv. Chronic Dis.* **7**, 18-33.
- Davenport, A. P., Alexander, S. P., Sharman, J. L., Pawson, A. J., Benson, H. E., Monaghan, A. E., Liew, W. C., Mpamhanga, C. P., Bonner, T. I., Neubig, R. R., Pin, J. P., Spedding, M. and Harmar, A. J. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. *Pharmacol. Rev.* **65**, 967-986.
- Eltzschig, H. K. and Collard, C. D. (2004) Vascular ischaemia and reperfusion injury. *Br. Med. Bull.* **70**, 71-86.
- Forrest, M., Sun, S. Y., Hajdu, R., Bergstrom, J., Card, D., Doherty, G., Hale, J., Keohane, C., Meyers, C., Milligan, J., Mills, S., Nomura, N., Rosen, H., Rosenbach, M., Shei, G. J., Singer, I., Tian, M., West, S., White, V., Xie, J., Proia, R. L. and Mandala, S. (2004) Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. *J. Pharmacol. Exp. Ther.* **309**, 758-768.
- Fredriksson, R., Lagerstrom, M. C., Lundin, L. G. and Schioth, H. B. (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Mol. Pharmacol.* **63**, 1256-1272.
- Fryer, R. M., Muthukumarana, A., Harrison, P. C., Nodop Mazurek, S., Chen, R. R., Harrington, K. E., Dinallo, R. M., Horan, J. C., Patnaude, L., Modis, L. K. and Reinhart, G. A. (2012) The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P<sub>1</sub>) and hypertension (S1P<sub>3</sub>) in rat. *PLoS ONE* **7**, e52985.
- Fu, Y., Hao, J., Zhang, N., Ren, L., Sun, N., Li, Y. J., Yan, Y., Huang, D., Yu, C. and Shi, F. D. (2014) Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. *JAMA Neurol.* **71**, 1092-1101.
- Fujishiro, J., Kudou, S., Iwai, S., Takahashi, M., Hakamata, Y., Kinoshita, M., Iwanami, S., Izawa, S., Yasue, T., Hashizume, K., Murakami, T. and Kobayashi, E. (2006) Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. *Transplantation* **82**, 804-812.
- Gardell, S. E., Dubin, A. E. and Chun, J. (2006) Emerging medicinal roles for lysophospholipid signaling. *Trends Mol. Med.* **12**, 65-75.
- Gergely, P., Nuesslein-Hildesheim, B., Guerini, D., Brinkmann, V., Traeber, M., Bruns, C., Pan, S., Gray, N. S., Hinterding, K., Cooke, N. G., Groenewegen, A., Vitaliti, A., Sing, T., Luttringer, O., Yang, J., Gardin, A., Wang, N., Crumb, W. J., Jr., Saltzman, M., Rosenberg, M. and Wallstrom, E. (2012) The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. *Br. J. Pharmacol.* **167**, 1035-1047.
- Germinario, E., Peron, S., Toniolo, L., Betto, R., Cencetti, F., Donati, C., Bruni, P. and Danielli-Betto, D. (2012) S1P2 receptor promotes mouse skeletal muscle regeneration. *J. Appl. Physiol.* **113**, 707-713.
- Gollmann, G., Neuwirt, H., Tripp, C. H., Mueller, H., Konwalinka, G., Heufler, C., Romani, N. and Tiefenthaler, M. (2008) Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions. *Int. Immunol.* **20**, 911-923.
- Goodemote, K. A., Mattie, M. E., Berger, A. and Spiegel, S. (1995) Involvement of a pertussis toxin-sensitive G protein in the mitogenic signaling pathways of sphingosine 1-phosphate. *J. Biol. Chem.* **270**, 10272-10277.
- Hashimoto, M., Wang, X., Mao, L., Kobayashi, T., Kawasaki, S., Mori, N., Toews, M. L., Kim, H. J., Ceruti, D. R., Liu, X. and Rennard, S. I. (2008) Sphingosine 1-phosphate potentiates human lung fibroblast chemotaxis through the S1P<sub>2</sub> receptor. *Am. J. Respir. Cell Mol. Biol.* **39**, 356-363.
- Hofmann, U., Burkard, N., Vogt, C., Thoma, A., Frantz, S., Ertl, G., Ritter, O. and Bonz, A. (2009) Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion. *Cardiovasc. Res.* **83**, 285-293.
- Hou, J., Chen, Q., Zhang, K., Cheng, B., Xie, G., Wu, X., Luo, C., Chen, L., Liu, H., Zhao, B., Dai, K. and Fang, X. (2015) Sphingosine 1-phosphate receptor 2 signaling suppresses macrophage phagocytosis and impairs host defense against sepsis. *Anesthesiology* **123**, 409-422.
- Howard, A. D., McAllister, G., Feighner, S. D., Liu, Q., Nargund, R. P., Van der Ploeg, L. H. and Patchett, A. A. (2001) Orphan G-protein-coupled receptors and natural ligand discovery. *Trends Pharmacol.*



- Sci.* **22**, 132-140.
- Hughes, J. E., Srinivasan, S., Lynch, K. R., Proia, R. L., Ferdek, P. and Hedrick, C. C. (2008) Sphingosine-1-phosphate induces an anti-inflammatory phenotype in macrophages. *Circ. Res.* **102**, 950-958.
- Huu, D. L., Matsushita, T., Jin, G., Hamaguchi, Y., Hasegawa, M., Takehara, K. and Fujimoto, M. (2013) FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. *Arthritis Rheum.* **65**, 1624-1635.
- Huwiler, A. and Pfeilschifter, J. (2008) New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. *Biochem. Pharmacol.* **75**, 1893-1900.
- Im, D. S. (2002) Orphan G protein-coupled receptors and beyond. *Jpn. J. Pharmacol.* **90**, 101-106.
- Im, D. S. (2003) Linking Chinese medicine and G-protein-coupled receptors. *Trends Pharmacol. Sci.* **24**, 2-4.
- Im, D. S. (2004) Discovery of new G protein-coupled receptors for lipid mediators. *J. Lipid. Res.* **45**, 410-418.
- Im, D. S. (2009) New intercellular lipid mediators and their GPCRs: an update. *Prostaglandins Other Lipid Medat.* **89**, 53-56.
- Im, D. S. (2010) Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. *Acta Pharmacol. Sin.* **31**, 1213-1222.
- Im, D. S. (2013) Intercellular lipid mediators and GPCR drug discovery. *Biomol. Ther. (Seoul)* **21**, 411-422.
- Im, D. S., Fujioka, T., Katada, T., Kondo, Y., Ui, M. and Okajima, F. (1997) Characterization of sphingosine 1-phosphate-induced actions and its signaling pathways in rat hepatocytes. *Am. J. Physiol.* **272**, G1091-G1099.
- Im, D. S., Heise, C. E., Ancellin, N., O'Dowd, B. F., Shei, G. J., Heavens, R. P., Rigby, M. R., Hla, T., Mandala, S., McAllister, G., George, S. R. and Lynch, K. R. (2000) Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. *J. Biol. Chem.* **275**, 14281-14286.
- Imasawa, T., Koike, K., Ishii, I., Chun, J. and Yatomi, Y. (2010) Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic b-cells. *Biochem. Biophys. Res. Commun.* **392**, 207-211.
- Ito, S., Iwaki, S., Koike, K., Yuda, Y., Nagasaki, A., Ohkawa, R., Yatomi, Y., Furumoto, T., Tsutsui, H., Sobel, B. E. and Fujii, S. (2013) Increased plasma sphingosine-1-phosphate in obese individuals and its capacity to increase the expression of plasminogen activator inhibitor-1 in adipocytes. *Coron. Artery Dis.* **24**, 642-650.
- Jackson, S. J., Giovannoni, G. and Baker, D. (2011) Fingolimod modulates microglial activation to augment markers of remyelination. *J. Neuroinflammation* **8**, 76.
- Japtok, L., Schmitz, E. I., Fayyaz, S., Kramer, S., Hsu, L. J. and Kleuser, B. (2015) Sphingosine 1-phosphate counteracts insulin signaling in pancreatic  $\beta$ -cells via the sphingosine 1-phosphate receptor subtype 2. *FASEB J.* **29**, 3357-3369.
- Kaneko, T., Murakami, T., Kawana, H., Takahashi, M., Yasue, T. and Kobayashi, E. (2006) Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. *Biochem. Biophys. Res. Commun.* **345**, 85-92.
- Kappos, L., Li, D. K., Stuve, O., Hartung, H. P., Freedman, M. S., Hemmer, B., Rieckmann, P., Montalban, X., Ziemssen, T., Hunter, B., Arnould, S., Wallstrom, E. and Selmaj, K. (2016) Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. *JAMA Neurol.* **73**, 1089-1098.
- Kappos, L., Radue, E. W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., Burtin, P. and Group, F. S. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N. Engl. J. Med.* **362**, 387-401.
- Kawata, T., Ishizuka, T., Tomura, H., Hisada, T., Dobashi, K., Tsukagoshi, H., Ishiwara, M., Kurose, H., Mori, M. and Okajima, F. (2005) Sphingosine 1-phosphate inhibits migration and RANTES production in human bronchial smooth muscle cells. *Biochem. Biophys. Res. Commun.* **331**, 640-647.
- Kihara, Y., Mizuno, H. and Chun, J. (2015) Lysophospholipid receptors in drug discovery. *Exp. Cell Res.* **333**, 171-177.
- Kim, G. S., Yang, L., Zhang, G., Zhao, H., Selim, M., McCullough, L. D., Kluk, M. J. and Sanchez, T. (2015) Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke. *Nat. Commun.* **6**, 7893.
- Kim, H. J., Jung, C. G., Dukala, D., Bae, H., Kakazu, R., Wollmann, R. and Soliven, B. (2009) Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy. *J. Neuroimmunol.* **214**, 93-100.
- Kitada, Y., Kajita, K., Taguchi, K., Mori, I., Yamauchi, M., Ikeda, T., Kawashima, M., Asano, M., Kajita, T., Ishizuka, T., Banno, Y., Kojima, I., Chun, J., Kamata, S., Ishii, I. and Morita, H. (2016) Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates high-fat diet-induced adipocyte hypertrophy and systemic glucose intolerance in mice. *Endocrinology* **157**, 1839-1851.
- Kolahdooz, Z., Nasoohi, S., Asle-Rousta, M., Ahmadiani, A. and Dargahi, L. (2015) Sphingosin-1-phosphate receptor 1: a potential target to inhibit neuroinflammation and restore the sphingosin-1-phosphate metabolism. *Can. J. Neurol. Sci.* **42**, 195-202.
- Komiya, T., Sato, K., Shioya, H., Inagaki, Y., Hagiya, H., Kozaki, R., Imai, M., Takada, Y., Maeda, T., Kurata, H., Kurono, M., Suzuki, R., Otsuki, K., Habashita, H. and Nakade, S. (2013) Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. *Clin. Exp. Immunol.* **171**, 54-62.
- Lee, J. F., Gordon, S., Estrada, R., Wang, L., Siow, D. L., Wattenberg, B. W., Lominadze, D. and Lee, M. J. (2009) Balance of S1P<sub>1</sub> and S1P<sub>2</sub> signaling regulates peripheral microvascular permeability in rat cremaster muscle vasculature. *Am. J. Physiol. Heart Circ. Physiol.* **296**, H33-H42.
- Lee, M. J., Van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S. and Hla, T. (1998) Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. *Science* **279**, 1552-1555.
- Li, C., Zheng, S., You, H., Liu, X., Lin, M., Yang, L. and Li, L. (2011) Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. *J. Hepatol.* **54**, 1205-1213.
- Li, Y. J., Chang, G. Q., Liu, Y., Gong, Y., Yang, C., Wood, K., Shi, F. D., Fu, Y. and Yan, Y. (2015) Fingolimod alters inflammatory mediators and vascular permeability in intracerebral hemorrhage. *Neurosci. Bull.* **31**, 755-762.
- Lien, Y. H., Yong, K. C., Cho, C., Igarashi, S. and Lai, L. W. (2006) S1P<sub>1</sub>-selective agonist, SEW2871, ameliorates ischemic acute renal failure. *Kidney Int.* **69**, 1601-1608.
- Liu, X., Yue, S., Li, C., Yang, L., You, H. and Li, L. (2011) Essential roles of sphingosine 1-phosphate receptor types 1 and 3 in human hepatic stellate cells motility and activation. *J. Cell. Physiol.* **226**, 2370-2377.
- Lublin, F., Miller, D. H., Freedman, M. S., Cree, B. A., Wolinsky, J. S., Weiner, H., Lubetzki, C., Hartung, H. P., Montalban, X., Uitdehaag, B. M., Merschhemke, M., Li, B., Putzki, N., Liu, F. C., Haring, D. A. and Kappos, L. (2016) Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet* **387**, 1075-1084.
- Lukas, S., Patnaude, L., Haxhinasto, S., Slavina, A., Hill-Drzewi, M., Horan, J. and Modis, L. K. (2014) No differences observed among multiple clinical S1P<sub>1</sub> receptor agonists (functional antagonists) in S1P<sub>1</sub> receptor down-regulation and degradation. *J. Biomol. Screen.* **19**, 407-416.
- Lynch, K. R. and Im, D. S. (1999) Life on the edge. *Trends Pharmacol. Sci.* **20**, 473-475.
- Makide, K., Uwamizu, A., Shinjo, Y., Ishiguro, J., Okutani, M., Inoue, A. and Aoki, J. (2014) Novel lysophospholipid receptors: their structure and function. *J. Lipid Res.* **55**, 1986-1995.
- Marsolais, D., Yagi, S., Kago, T., Leaf, N. and Rosen, H. (2011) Modulation of chemokines and allergic airway inflammation by selective local sphingosine-1-phosphate receptor 1 agonism in lungs. *Mol. Pharmacol.* **79**, 61-68.
- Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L. and Cyster, J. G. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. *Nature* **427**, 355-360.
- Moberly, J. B., Ford, D. M., Zahir, H., Chen, S., Mochizuki, T., Truitt,

- K. E. and Vollmer, T. L. (2012a) Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients. *J. Neuroimmunol.* **246**, 100-107.
- Moberly, J. B., Rohatagi, S., Zahir, H., Hsu, C., Noveck, R. J. and Trutt, K. E. (2012b) Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator. *J. Clin. Pharmacol.* **52**, 996-1006.
- Moolenaar, W. H. and Hla, T. (2012) SnapShot: Bioactive lysophospholipids. *Cell* **148**, 378-378.e2.
- Mutoh, T., Rivera, R. and Chun, J. (2012) Insights into the pharmacological relevance of lysophospholipid receptors. *Br. J. Pharmacol.* **165**, 829-844.
- Nishi, T., Miyazaki, S., Takemoto, T., Suzuki, K., Iio, Y., Nakajima, K., Ohnuki, T., Kawase, Y., Nara, F., Inaba, S., Izumi, T., Yuita, H., Oshima, K., Doi, H., Inoue, R., Tomisato, W., Kagari, T. and Shimozato, T. (2011) Discovery of CS-0777: a potent, selective, and orally active S1P<sub>1</sub> agonist. *ACS Med. Chem. Lett.* **2**, 368-372.
- Noda, H., Takeuchi, H., Mizuno, T. and Suzumura, A. (2013) Fingolimod phosphate promotes the neuroprotective effects of microglia. *J. Neuroimmunol.* **256**, 13-18.
- Nofer, J. R., Bot, M., Brodde, M., Taylor, P. J., Salm, P., Brinkmann, V., van Berkel, T., Assmann, G. and Biessen, E. A. (2007) FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. *Circulation* **115**, 501-508.
- O'Sullivan, C., Schubart, A., Mir, A. K. and Dev, K. K. (2016) The dual S1P<sub>1</sub>/S1P<sub>5</sub> drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. *J. Neuroinflammation* **13**, 31.
- Ogawa, R., Takahashi, M., Hirose, S., Morimoto, H., Ise, H., Murakami, T., Yasue, T., Kuriyama, K., Hongo, M., Kobayashi, E. and Ikeda, U. (2007) A novel sphingosine-1-phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis. *Biochem. Biophys. Res. Commun.* **361**, 621-628.
- Ohno, T., Hasegawa, C., Nakade, S., Kitagawa, J., Honda, N. and Ogawa, M. (2010) The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling. *Biopharm. Drug Dispos.* **31**, 396-406.
- Okajima, F., Tomura, H., Sho, K., Kimura, T., Sato, K., Im, D. S., Akbar, M. and Kondo, Y. (1997) Sphingosine 1-phosphate stimulates hydrogen peroxide generation through activation of phospholipase C-Ca<sup>2+</sup> system in FRTL-5 thyroid cells: possible involvement of guanosine triphosphate-binding proteins in the lipid signaling. *Endocrinology* **138**, 220-229.
- Okamoto, H., Takuwa, N., Yatomi, Y., Gonda, K., Shigematsu, H. and Takuwa, Y. (1999) EDG3 is a functional receptor specific for sphingosine 1-phosphate and sphingosylphosphorylcholine with signaling characteristics distinct from EDG1 and AGR16. *Biochem. Biophys. Res. Commun.* **260**, 203-208.
- Olivera, A. and Spiegel, S. (1993) Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. *Nature* **365**, 557-560.
- Olsson, T., Boster, A., Fernandez, O., Freedman, M. S., Pozzilli, C., Bach, D., Berkani, O., Mueller, M. S., Sidorenko, T., Radue, E. W. and Melanson, M. (2014) Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. *J. Neurol. Neurosurg. Psychiatr.* **85**, 1198-1208.
- Oo, M. L., Thangada, S., Wu, M. T., Liu, C. H., Macdonald, T. L., Lynch, K. R., Lin, C. Y. and Hla, T. (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. *J. Biol. Chem.* **282**, 9082-9089.
- Osada, M., Yatomi, Y., Ohmori, T., Ikeda, H. and Ozaki, Y. (2002) Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. *Biochem. Biophys. Res. Commun.* **299**, 483-487.
- Oskeritzian, C. A., Hait, N. C., Wedman, P., Chumanovich, A., Kolawole, E. M., Price, M. M., Falanga, Y. T., Harikumar, K. B., Ryan, J. J., Milstien, S., Sabbadini, R. and Spiegel, S. (2015) The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses. *J. Allergy Clin. Immunol.* **135**, 1008-1018.e1.
- Oskeritzian, C. A., Price, M. M., Hait, N. C., Kapitonov, D., Falanga, Y. T., Morales, J. K., Ryan, J. J., Milstien, S. and Spiegel, S. (2010) Essential roles of sphingosine-1-phosphate receptor 2 in human mast cell activation, anaphylaxis, and pulmonary edema. *J. Exp. Med.* **207**, 465-474.
- Overington, J. P., Al-Lazikani, B. and Hopkins, A. L. (2006) How many drug targets are there? *Nat. Rev. Drug Discov.* **5**, 993-996.
- Pan, S., Mi, Y., Pally, C., Beerli, C., Chen, A., Guerini, D., Hinterding, K., Nuesslein-Hildesheim, B., Tuntland, T., Lefebvre, S., Liu, Y., Gao, W., Chu, A., Brinkmann, V., Bruns, C., Streiff, M., Cannet, C., Cooke, N. and Gray, N. (2006) A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. *Chem. Biol.* **13**, 1227-1234.
- Park, S. W., Kim, M., Chen, S. W., Brown, K. M., D'Agati, V. D. and Lee, H. T. (2010) Sphinganine-1-phosphate protects kidney and liver after hepatic ischemia and reperfusion in mice through S1P<sub>1</sub> receptor activation. *Lab. Invest.* **90**, 1209-1224.
- Paugh, S. W., Payne, S. G., Barbour, S. E., Milstien, S. and Spiegel, S. (2003) The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. *FEBS Lett.* **554**, 189-193.
- Piali, L., Froidevaux, S., Hess, P., Nayler, O., Bolli, M. H., Schlosser, E., Kohl, C., Steiner, B. and Clozel, M. (2011) The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. *J. Pharmacol. Exp. Ther.* **337**, 547-556.
- Poti, F., Costa, S., Bergonzini, V., Galletti, M., Pignatti, E., Weber, C., Simoni, M. and Nofer, J. R. (2012) Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R<sup>-/-</sup>) mice. *Vascul. Pharmacol.* **57**, 56-64.
- Poti, F., Gualtieri, F., Sacchi, S., Weissen-Plenz, G., Varga, G., Brodde, M., Weber, C., Simoni, M. and Nofer, J. R. (2013) KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R<sup>-/-</sup> mice. *Arterioscler. Thromb. Vasc. Biol.* **33**, 1505-1512.
- Proia, R. L. and Hla, T. (2015) Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. *J. Clin. Invest.* **125**, 1379-1387.
- Pyne, N. J., Tonelli, F., Lim, K. G., Long, J. S., Edwards, J. and Pyne, S. (2012) Sphingosine 1-phosphate signalling in cancer. *Biochem. Soc. Trans.* **40**, 94-100.
- Rivera-Nieves, J. (2015) Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments. *Curr. Opin. Gastroenterol.* **31**, 441-448.
- Sammani, S., Moreno-Vinasco, L., Mirzapozdova, T., Singleton, P. A., Chiang, E. T., Evenoski, C. L., Wang, T., Mathew, B., Husain, A., Moitra, J., Sun, X., Nunez, L., Jacobson, J. R., Dudek, S. M., Natarajan, V. and Garcia, J. G. (2010) Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung. *Am. J. Respir. Cell Mol. Biol.* **43**, 394-402.
- Sanchez, T. and Hla, T. (2004) Structural and functional characteristics of S1P receptors. *J. Cell. Biochem.* **92**, 913-922.
- Sandborn, W. J., Feagan, B. G., Wolf, D. C., D'Haens, G., Vermeire, S., Hanauer, S. B., Ghosh, S., Smith, H., Cravets, M., Frohna, P. A., Aranda, R., Gujrathi, S. and Olson, A. (2016) Ozanimod induction and maintenance treatment for ulcerative colitis. *N. Engl. J. Med.* **374**, 1754-1762.
- Sanna, M. G., Liao, J., Jo, E., Alfonso, C., Ahn, M. Y., Peterson, M. S., Webb, B., Lefebvre, S., Chun, J., Gray, N. and Rosen, H. (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P<sub>1</sub> and S1P<sub>3</sub>, respectively, regulate lymphocyte recirculation and heart rate. *J. Biol. Chem.* **279**, 13839-13848.
- Scott, F. L., Clemons, B., Brooks, J., Brahmachary, E., Powell, R., Dedman, H., Desale, H. G., Timony, G. A., Martinborough, E., Rosen, H., Roberts, E., Boehm, M. F. and Peach, R. J. (2016) Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P<sub>1</sub>) and receptor-5 (S1P<sub>5</sub>) agonist with autoimmune disease-modifying activity. *Br. J. Pharmacol.* **173**, 1778-1792.
- Selmaj, K., Li, D. K., Hartung, H. P., Hemmer, B., Kappos, L., Freed-

- man, M. S., Stuve, O., Rieckmann, P., Montalban, X., Ziemssen, T., Auberson, L. Z., Pohlmann, H., Mercier, F., Dahlke, F. and Wallstrom, E. (2013) Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. *Lancet Neurol.* **12**, 756-767.
- Shea, B. S., Brooks, S. F., Fontaine, B. A., Chun, J., Luster, A. D. and Tager, A. M. (2010) Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. *Am. J. Respir. Cell Mol. Biol.* **43**, 662-673.
- Shimizu, H., Takahashi, M., Kaneko, T., Murakami, T., Hakamata, Y., Kudou, S., Kishi, T., Fukuchi, K., Iwanami, S., Kuriyama, K., Yasue, T., Enosawa, S., Matsumoto, K., Takeyoshi, I., Morishita, Y. and Kobayashi, E. (2005) KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. *Circulation* **111**, 222-229.
- Skoura, A., Michaud, J., Im, D. S., Thangada, S., Xiong, Y., Smith, J. D. and Hla, T. (2011) Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* **31**, 81-85.
- Song, J., Matsuda, C., Kai, Y., Nishida, T., Nakajima, K., Mizushima, T., Kinoshita, M., Yasue, T., Sawa, Y. and Ito, T. (2008) A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. *J. Pharmacol. Exp. Ther.* **324**, 276-283.
- Stone, M. L., Sharma, A. K., Zhao, Y., Charles, E. J., Huerter, M. E., Johnston, W. F., Kron, I. L., Lynch, K. R. and Laubach, V. E. (2015) Sphingosine-1-phosphate receptor 1 agonism attenuates lung ischemia-reperfusion injury. *Am. J. Physiol. Lung Cell Mol. Physiol.* **308**, L1245-L1252.
- Subei, A. M. and Cohen, J. A. (2015) Sphingosine 1-phosphate receptor modulators in multiple sclerosis. *CNS Drugs* **29**, 565-575.
- Takahashi, M., Shimizu, H., Murakami, T., Enosawa, S., Suzuki, C., Takeno, Y., Hakamata, Y., Kudou, S., Izawa, S., Yasue, T. and Kobayashi, E. (2005) A novel immunomodulator KRP-203 combined with cyclosporine prolonged graft survival and abrogated transplant vasculopathy in rat heart allografts. *Transplant. Proc.* **37**, 143-145.
- Thangada, S., Khanna, K. M., Blaho, V. A., Oo, M. L., Im, D. S., Guo, C., Lefrancois, L. and Hla, T. (2010) Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. *J. Exp. Med.* **207**, 1475-1483.
- Trifilieff, A., Baur, F. and Fozard, J. R. (2009) Role of sphingosine-1-phosphate (S1P) and the S1P<sub>2</sub> receptor in allergen-induced, mast cell-dependent contraction of rat lung parenchymal strips. *Naunyn Schmiedeberg's Arch. Pharmacol.* **380**, 303-309.
- Trifilieff, A. and Fozard, J. R. (2012) Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor. *J. Pharmacol. Exp. Ther.* **342**, 399-406.
- Vaclavkova, A., Chimenti, S., Arenberger, P., Hollo, P., Sator, P. G., Burcklen, M., Stefani, M. and D'Ambrosio, D. (2014) Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet* **384**, 2036-2045.
- Van Brocklyn, J. R., Graler, M. H., Bernhardt, G., Hobson, J. P., Lipp, M. and Spiegel, S. (2000) Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. *Blood* **95**, 2624-2629.
- van Koppen, C., Meyer zu Heringdorf, M., Laser, K. T., Zhang, C., Jakobs, K. H., Bunemann, M. and Pott, L. (1996) Activation of a high affinity Gi protein-coupled plasma membrane receptor by sphingosine-1-phosphate. *J. Biol. Chem.* **271**, 2082-2087.
- Wang, M., Lu, L., Liu, Y., Gu, G. and Tao, R. (2014) FTY720 attenuates hypoxia-reoxygenation-induced apoptosis in cardiomyocytes. *Exp. Mol. Pathol.* **97**, 218-224.
- Wei, S. H., Rosen, H., Matheu, M. P., Sanna, M. G., Wang, S. K., Jo, E., Wong, C. H., Parker, I. and Cahalan, M. D. (2005) Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. *Nat. Immunol.* **6**, 1228-1235.
- Whetzel, A. M., Bolick, D. T., Srinivasan, S., Macdonald, T. L., Morris, M. A., Ley, K. and Hedrick, C. C. (2006) Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P<sub>1</sub> receptor. *Circ. Res.* **99**, 731-739.
- Xie, J. H., Nomura, N., Koprak, S. L., Quackenbush, E. J., Forrest, M. J. and Rosen, H. (2003) Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4<sup>+</sup> T cells. *J. Immunol.* **170**, 3662-3670.
- Xu, J., Gray, F., Henderson, A., Hicks, K., Yang, J., Thompson, P. and Oliver, J. (2014) Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers. *Clin. Pharmacol. Drug Dev.* **3**, 170-178.
- Yamazaki, Y., Kon, J., Sato, K., Tomura, H., Sato, M., Yoneya, T., Okazaki, H., Okajima, F. and Ohta, H. (2000) Edg-6 as a putative sphingosine 1-phosphate receptor coupling to Ca<sup>2+</sup> signaling pathway. *Biochem. Biophys. Res. Commun.* **268**, 583-589.
- Yokoo, E., Yatomi, Y., Takafuta, T., Osada, M., Okamoto, Y. and Ozaki, Y. (2004) Sphingosine 1-phosphate inhibits migration of RBL-2H3 cells via S1P<sub>2</sub>: cross-talk between platelets and mast cells. *J. Biochem.* **135**, 673-681.
- You, S., Piali, L., Kuhn, C., Steiner, B., Sauvaget, V., Valette, F., Clozel, M., Bach, J. F. and Chatenoud, L. (2013) Therapeutic use of a selective S1P<sub>1</sub> receptor modulator ponesimod in autoimmune diabetes. *PLoS ONE* **8**, e77296.
- Zhang, G., Yang, L., Kim, G. S., Ryan, K., Lu, S., O'Donnell, R. K., Spokes, K., Shapiro, N., Aird, W. C., Kluk, M. J., Yano, K. and Sanchez, T. (2013) Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation. *Blood* **122**, 443-455.
- Zhang, Z. Y., Zhang, Z. and Schluesener, H. J. (2009a) FTY720 attenuates lesional interleukin-17<sup>+</sup> cell accumulation in rat experimental autoimmune neuritis. *Neuropathol. Appl. Neurobiol.* **35**, 487-495.
- Zhang, Z. Y., Zhang, Z., Zug, C., Nuesslein-Hildesheim, B., Leppert, D. and Schluesener, H. J. (2009b) AU954, a selective S1P<sub>1</sub> modulator, prevents experimental autoimmune neuritis. *J. Neuroimmunol.* **216**, 59-65.
- Zhu, Z., Fu, Y., Tian, D., Sun, N., Han, W., Chang, G., Dong, Y., Xu, X., Liu, Q., Huang, D. and Shi, F. D. (2015) Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. *Circulation* **132**, 1104-1112.